Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$0.37.

  • Amylyx Pharmaceuticals' EPS (Basic) rose 6542.06% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year increase of 5314.14%. This contributed to the annual value of -$4.43 for FY2024, which is 70684.93% down from last year.
  • Amylyx Pharmaceuticals' EPS (Basic) amounted to -$0.37 in Q3 2025, which was up 6542.06% from -$0.46 recorded in Q2 2025.
  • Amylyx Pharmaceuticals' EPS (Basic)'s 5-year high stood at $0.33 during Q2 2023, with a 5-year trough of -$4.15 in Q4 2021.
  • Its 5-year average for EPS (Basic) is -$1.14, with a median of -$0.92 in 2022.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 13548.39% in 2023, then crashed by 885000.0% in 2024.
  • Amylyx Pharmaceuticals' EPS (Basic) (Quarter) stood at -$4.15 in 2021, then surged by 85.06% to -$0.62 in 2022, then soared by 111.29% to $0.07 in 2023, then crashed by 871.43% to -$0.54 in 2024, then soared by 31.48% to -$0.37 in 2025.
  • Its EPS (Basic) was -$0.37 in Q3 2025, compared to -$0.46 in Q2 2025 and -$0.42 in Q1 2025.